Zobrazeno 1 - 10
of 318
pro vyhledávání: '"David V. Sheehan"'
Autor:
Larry, Alphs, Dong-Jing, Fu, David, Williamson, Carol, Jamieson, John, Greist, Magdalena, Harrington, Jean-Pierre, Lindenmayer, Cheryl, McCullumsmith, David V, Sheehan, Richard C, Shelton, Paul, Wicks, Carla M, Canuso
Publikováno v:
Innov Clin Neurosci
OBJECTIVE: Most assessments of suicidal ideation and behavior (SIB) are limited by reliance on a single assessor, typically a clinician or patient, with scant detail on patient-related drivers of SIB and inability to detect rapid change in SIB. Furth
Autor:
Ritambhara Y Mehta, Lokesh Kumar Singh, Theerthankara Meethal Shibukumar, Pradeep Kumar Saha, Gopalkrishna Gururaj, Bir Singh Chavan, Pronob Kumar Dalal, Chellamuthu Ramasubramanian, Mathew Varghese, Arun M Kokane, Vivek Benegal, Senthil Amudhan, Daya Ram, David V. Sheehan, Girish N Rao, Kangkan Pathak, Raj Kumar Lenin Singh, Pradeep Sharma
Publikováno v:
The Lancet Psychiatry. 7:41-51
India accounts for 18% of the global population and 26·6% of global suicide deaths. However, robust population-based, nationally representative data on suicidality are not readily available to plan and implement suicide prevention programmes in Indi
Publikováno v:
International Journal of Methods in Psychiatric Research
Objectives This study examined Sheehan Disability Scale (SDS) performance in binge eating disorder (BED) and explored relationships between SDS and BED outcomes using data from three placebo‐controlled lisdexamfetamine (LDX) studies (two short‐te
Autor:
Suresh Durgam, David V. Sheehan, Giovanna Forero, Xiongwen Tang, Rene Nunez, Carl Gommoll, Maju Mathews
Publikováno v:
The Journal of Clinical Psychiatry. 77:1687-1694
Objective To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist approved for the treat
Autor:
Mariam Hassan, Julie C. Locklear, Hans Eriksson, Dennis A. Revicki, Sajjad Wali Khan, Dunbar Geoffrey Charles, Sally Mannix, David V. Sheehan, Raj Tummala
Publikováno v:
International Clinical Psychopharmacology. 31:110-117
The Sheehan Irritability Scale (SIS) measures the frequency, severity, and impairment associated with irritability in psychiatric patients. The content validity of the SIS in patients with major depressive disorder (MDD) has not been evaluated. A cro
Publikováno v:
Scopus-Elsevier
Objective: In two Phase III, randomized, placebo-controlled trials (NCT01718483 and NCT01718509 at ClinicalTrials.gov), lisdexamfetamine dimesylate (LDX) reduced binge eating days/week in adults with moderate-to-severe binge eating disorder (BED). We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a1bae63e820cb3e0c1cda15f4299d9e3
https://europepmc.org/articles/PMC6040726/
https://europepmc.org/articles/PMC6040726/
Autor:
Haijun Cao, Héctor José Dueñas, Li Yue, Jianing Wang, Michele Mancini, Lovisa Berggren, David V. Sheehan
Publikováno v:
Human Psychopharmacology
Objective We compared functional impairment outcomes assessed with Sheehan Disability Scale (SDS) after treatment with duloxetine versus selective serotonin reuptake inhibitors (SSRIs) in patients with major depressive disorder. Methods Data were poo
Publikováno v:
Journal of affective disorders. 215
Background Functional impairment contributes to significant disability and economic burden in major depressive disorder (MDD). Treatment response is measured by improvement in depressive symptoms, but functional improvement often lags behind symptoma
Autor:
Anjana Bose, Changzheng Chen, Carl Gommoll, William M. Greenberg, Angelo Sambunaris, David V. Sheehan
Publikováno v:
Journal of Clinical Psychopharmacology
Major depressive disorder (MDD) is a leading cause of global disease burden; by 2030, it is projected that it will be only second to human immunodeficiency virus/acquired immunodeficiency syndrome in worldwide burden of disease.1 Some defining sympto
Autor:
Anthony L, Vaccarino, Kenneth R, Evans, Amir H, Kalali, Sidney H, Kennedy, Nina, Engelhardt, Benicio N, Frey, John H, Greist, Kenneth A, Kobak, Raymond W, Lam, Glenda, MacQueen, Roumen, Milev, Franca M, Placenza, Arun V, Ravindran, David V, Sheehan, Terrence, Sills, Janet B W, Williams
Publikováno v:
Innovations in clinical neuroscience. 13(9-10)
The Depression Inventory Development project is an initiative of the International Society for CNS Drug Development whose goal is to develop a comprehensive and psychometrically sound measurement tool to be utilized as a primary endpoint in clinical